Research groups such as Tokushima University and Kumamoto University in Japan have published the successful development of compounds that may be useful for the treatment of refractory cancers such as melanoma (malignant melanoma). It is said that after combining with existing anticancer agents, the mice with melanoma reduced the tumor size to less than a quarter. Published thesis in the German scientific journal "Advanced Basic Materials".
In cancers that are considered difficult to treat such as melanoma, there are two types of cells called "stromal cells" that surround the cancer cells,
Associate Professor Ishima Yu of Tokushima University, Professor Toru Maruyama of Kumamoto University, Assistant Professor Toshi Maeda, and Researcher Yusei Mizuta and other groups have improved the harmless compounds that originally existed in the body, so that the two kinds of mesenchymal cells successfully possess The nature of adsorption and invasion. In order to easily flow in the blood to reach the cancer tissue, the molecular structure is changed.
When this compound is given to mice with melanoma, it will accumulate in cancer tissues. It was also confirmed that if this compound is combined with the anticancer agent "paclitaxel" and injected into mice, the cancer cell tissue will rapidly become smaller. Only injecting paclitaxel has almost no effect.
Associate Professor Ishima said: "It has been confirmed that the tumor itself can be reduced by not directly tapping the cancer cells, but by reducing the
follow us private message for more regeneration information
.
